Atlas Trials

Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.

Clinical trial NCT06417801 · RECRUITING

Trial details

NCT number
NCT06417801
Sponsor
AstraZeneca
Status
RECRUITING
Study type
OBSERVATIONAL
Metastatic Breast Cancer
Start date
2024-06-17
Primary completion
2027-12-30
Enrollment
170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.